Options trading in Boston Scientific Corporation experienced an abrupt jump on September 1, with total volume reaching 118,890 contracts by 2:30 p.m. That activity was overwhelmingly tilted toward calls, which accounted for 113,223 contracts, while puts represented just 5,667 contracts. The flow points to a concentrated, bullish approach from traders active in the name.
The most prominent element of the session was a large December vertical call spread: a combined 100,144 contracts split evenly between the December 18, 2026 $60 calls and the $75 calls (50,072 contracts each). This structure is a standard vertical call spread where traders acquire the lower-strike calls and sell the higher-strike calls, thereby creating limited-risk, limited-reward exposure to an upward move in the underlying stock.
Open interest ahead of the session was considerably smaller than the day’s volume, measuring 9,072 contracts on the $60 calls and 1,196 contracts on the $75 calls. The disparity between today's trade volume and existing open interest suggests the trades represent largely new positions rather than mere transfers of existing contracts, consistent with organized institutional-sized entries.
What the options market is signaling
The choice of a $60-$75 call spread frames expectations: market participants appear to be positioning for a solid recovery in the stock, but not for an open-ended rally. The $60-$75 range implies upside expectations of roughly 25% to 56% versus the current share price of $48.09.
Other options activity was present but dwarfed by the December spread. Notable among smaller trades was a January 2027 $55 call with 5,022 contracts, and various September puts and calls indicating some hedging and short-term positioning. On the volatility front, three-month implied volatility eased to 41.23% - down 1.70 points - and skew fell by 0.81%, reflecting a reduction in perceived tail risk as dealers hedged positions and bought stock to offset large call exposure.
Why the trade matters for Boston Scientific
The magnitude and structure of the December call spread point to institutional conviction that Boston Scientific can rebound by late in the year. That view comes despite a difficult recent performance for the equity: the stock is down 54.2% over the past 12 months and is trading at $48.09, a long way below its $109.50 all-time high.
Analyst targets clustering in the $60-$63 area align with the lower leg of the December spread, creating an apparent connection between sell-side expectations and the options play. In addition, recent corporate developments referenced by market participants include a director purchase of over $100,000 in shares and ongoing share buybacks, factors that add a modest bullish backdrop to the large options position. At the same time, an ongoing cybersecurity incident that has disrupted global operations remains an active risk that may keep volatility elevated in the near term.
What to watch next
The December spread is a conventional institutional strategy that offers exposure to a rally while limiting downside and upside beyond the spread’s strikes. Market participants will likely monitor any updates on the cybersecurity incident and forthcoming company news, including earnings, as potential catalysts. Should the stock move toward $60, trading in related options contracts would be expected to accelerate as the market reprices the probability of the spread finishing in the money.
In short, the session’s flow signals a coordinated, bullish wager with risk controls built into the structure - a clear example of how large investors can express directional views in listed options while managing payoff characteristics.